NCT05675982Active, not recruiting
Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells
Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With Anti-CD19 CAR-T Cells for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
The purpose of this study is to demonstrate that it is possible to report in real time (less than 3 weeks) to the hematologist the results of the molecular minimal residual disease (MRD) based on blood circulating tumor DNA (ctDNA) assessment taken approximately 7 days after the reinjection of the CAR-T cells, in order to be able to anticipate a possible progression of the disease and to be able to propose salvage or earlier adjuvant therapy to improve patient prognosis.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 22 Dec 2022
- Start date
- Jan 2023
- Primary completion date
- Sept 2025
- Lead sponsor
- Centre Henri Becquerel
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT05675982
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From Jan 2023 to the primary completion date, Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient treated with CAR-T as part of a therapeutic clinical trial
Other illness
- Absence or insufficiency of tumor material (patient's most recent diagnostic biopsy) fixed in FFPE paraffin of insufficient quality/quantity for next-generation sequencing (NGS) analysis
Other
- Pregnant or breastfeeding women
- Lack of patient consent
- Patient whose weight is less than 30 kg
- Protected adult or deprived of liberty (under guardianship or curatorship)
- Patient unable to understand the study for any reason whatsoever or to comply with the constraints of the trial (language, psychological, geographic problem, etc.).
Who the study is looking for
- Patients aged 18 or over
- Carriers of relapsed or refractory diffuse large cell B-cell lymphoma (LBDGC R/R), relapsed or refractory primary mediastinum B-cell lymphoma or follicular lymphoma transformed into LBDGC R/R
- Patients with an indication for treatment with CAR-T anti CD19
- PET-CT pre-injection of CAR-T performed
- Signed informed consent
- Patients affiliated or beneficiaries of a health insurance scheme
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Henri Becquerel Coordinator of this site? Confirm its status | Rouen | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.